Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Presentation (September 2023)
81 slides from Qiagen's investor presentation, September 2023
Slide 1: Making improvements in life possible – Investor resource book
Making improvements in life possible Investor resource book September 2023
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be forward looking statements within the meaning of Section 27A of the U.S. S
Slide 3: Table of Contents
Table of Contents About QIAGEN 4 QIAGEN at a glance 5 Business areas 16 Strategy 18 Global presence 20 Debt information 24 Capital allocation 25 Why invest 26 Product portfolios 27 Sample technologies 29 Diagnostic solutions 34 PCR / Nucleic acid amplification 51 Genomics / NGS 59 Sustainability 67
Slide 4: We help advance science and improve outcomes
We help advance science and improve outcomes Our Mission Enabling access to valuable insights from molecular research to clinical healthcare Our Vision Making improvements in life possible Investor Resource Book 4
Slide 5: QIAGEN at a glance
QIAGEN at a glance A global company with scale ~45% $2.1 Americas billion Sales ~35% (2022 (2022) EMEA sales) ~20% Asia-Pacific / Japan Highly recurring revenues Balanced customer markets ~6,200 employees known as QIAGENers ~ 88% 12% ~ ~ 50% 50% ~ Consumables and related revenues Instruments Molecul
Slide 6: QIAGEN solutions are used across the world
QIAGEN solutions are used across the world by researchers - from young scientists to Nobel laureates - and clinical testing labs Investor Resource Book 6
Slide 7: More than 3 billion samples have been processed
More than 3 billion samples have been processed using QIAGEN sample preparation kits Dr. Darren Chooneea Research Scientist, London Natural History Museum Uses QIAGEN’s PowerSoil Pro Kit to explore the evolution of microorganisms as they adapted to changing environmental conditions and identify the
Slide 8: More than 100 million patients have been screened
More than 100 million patients have been screened with QIAGEN’s latent TB test Dr. Kiyoyasu Fukushima Japan Red Cross Nagasaki Genbaku Isahaya Hospital Employs QuantiFERON TB Plus for latent tuberculosis detection to ultimately reduce Japan‘s high infection rate Investor Resource Book 8
Slide 9: More than 4 million samples have been processed
More than 4 million samples have been processed with QIAGEN’s NGS kits Asha Palat and Brandon Mistretta University of Houston’s Department of Biology and Biochemistry Use QIAGEN’s QIAseq FastSelect RNA Removal Kits with next-generation sequencing (NGS) to develop more effective and more humane cance
Slide 10: QIAGEN is developing companion diagnostics
QIAGEN is developing companion diagnostics with over 25 Pharma companies Dr. Philippe Taniere Consultant histopathologist Queen Elizabeth Hospital Birmingham Relies on QIAGEN’s standardized, regulatory- approved tests for KRAS, BRAF and EGFR to break the cellular code of cancer and find the right tr
Slide 11: Every 10 seconds a crime scene sample is analyzed
Every 10 seconds a crime scene sample is analyzed with QIAGEN kits Rachel Oefelein Chief Scientific Officer at DNA Labs International Helping to bring closure to victims and their families by using QIAGEN’s forensic genetic genealogy tools to enable identification of assailants by matching genetic r
Slide 12: QIAGEN's innovative instrument portfolio
QIAGEN’s innovative instrument portfolio tackles a variety of molecular applications Dr. Johanna Andersson-Assarsson University of Gothenburg Uses QIAGEN’s QIAcuity digital PCR platform to identify obesity gene variations that could help in the development of new therapies Investor Resource Book 12
Slide 13: QIAGEN products are known for the highest quality
QIAGEN products are known for the highest quality Investing in R&D and best-in-class manufacturing is a top priority Investor Resource Book 13
Slide 14: Providing Sample to Insight solutions
Providing Sample to Insight solutions to uncover molecular insights faster, better and more efficiently Sample technologies Assay technologies Discovery research Advancing understanding of life Pharma Faster and better drug R&D Clinical diagnostics Sample to Insight solutions Accurate disease diagno
Slide 15: We are helping over 500,000 customers
We are helping over 500,000 customers to unlock molecular insights Investor Resource Book 15
Slide 16: Life sciences: Working to enable scientific advancements
Life sciences: Working to enable scientific advancements QIAGEN value Academic research 2022 sales ~$1 billion Pharma development Recognized innovator supporting scientific breakthroughs Able to translate innovations Applied testing into commercial products ~$5 billion addressable market Selected QI
Slide 17: Molecular Diagnostics: Helping to improve outcomes in healthcare
Molecular Diagnostics: Helping to improve outcomes in healthcare QIAGEN value Immune response 2022 sales ~$1.1 billion Infectious diseases Addressing testing areas with high or growing demand Strong automation portfolio Oncology with multi-year assay menu expansion underway ~$6 billion addressable m
Slide 18: Our Strategy: Leveraging a strong core portfolio
Our Strategy: Leveraging a strong core portfolio to drive Pillars of Growth Expanding on solid leadership Early commercialization phases with strong growth potential Sample QuantiFERON QIAstat-Dx NeuMoDx QIAcuity technologies Leading immune Syndromic testing with Differentiated microfluidic Novel mi
Slide 19: We employ ~6,200 passionate QIAGENers
We employ ~6,200 passionate QIAGENers around the world from diverse backgrounds and locations Investor Resource Book 19
Slide 20: Our strong global presence serves both developed and emerging markets
Our strong global presence serves both developed and emerging markets >30 Our global Direct sales in and regional headquarters: Venlo Netherlands Germantown Global HQ countries Maryland Americas HQ Hilden Germany EMEA HQ Shanghai China HQ Singapore >170 Shipping product to Asia-Pacific HQ countries
Slide 21: FY 2022: +14% CER growth in non-COVID product groups
FY 2022: +14% CER growth in non-COVID product groups Non-COVID / COVID split By product group (In $ millions at actual rates) (In $ millions at actual rates) -5% -5% (+0% CER) (+0% CER) $2,252 $2,252 $2,142 $2,142 851 Sample -1% CER 797 technologies Non-COVID 1,547 1,672 product groups +14% CER Diag
Slide 22: Outlook: Q3 and FY 2023
Outlook: Q3 and FY 2023 Q3 2023 outlook Updated FY 2023 outlook (As of August 8, 2023) Net sales ≥ $465 million CER ≥ $1.97 billion CER Anticipated currency impact Up to ~1 percentage point benefit Neutral FX impact (Prior ≥ $2.05 billion CER) ≥ $2.07 CER Adjusted diluted EPS ≥ $0.48 CER Neutral FX
Slide 23: FY 2022: Leveraging strong cash flow to build sustainable growth
FY 2022: Leveraging strong cash flow to build sustainable growth Operating cash flow Free cash flow (In $ millions) (In $ millions) Targeted investments into five pillars + 12% + 30% High level of R&D investments into menu expansion for QIAstat-Dx, NeuMoDx and QIAcuity $715 $586 586 $639 Proactively
Slide 24: Maintaining financial flexibility with appropriate leverage
Maintaining financial flexibility with appropriate leverage Structure as of December 31, 2022 Maturities of debt instruments (In $ millions) $1.91 billion $1.42 billion Cash and short-term Convertible Bonds German Private Placement (Schuldschein) Convertible investments Bonds 117 2023 2024 601 613 2
Slide 25: Capital allocation: Strong balance sheet to create greater value
Capital allocation: Strong balance sheet to create greater value Investing in growth Healthy cash flow and leverage ratio trends $ Expanding test menus and millions manufacturing capacity, 800 1.6x especially in the five pillars 700 1.5x 1.4x 600 Enhance value with M&A 500 Ongoing disciplined approa
Slide 26: Why invest: Well-diversified business spanning attractive markets
Why invest: Well-diversified business spanning attractive markets Diversified Broad Highly customer base geographic reach recurring revenues Well-balanced leadership in ~6,200 QIAGENers ensuring Growing installed base Life Sciences and access to attractive markets with generating demand for Molecula
Slide 27: QIAGEN product portfolios
QIAGEN product portfolios
Slide 28: Sales reporting: Product groups
Sales reporting: Product groups QIAGEN Growth Pillars product groups Sample technologies(1) QIAcuity digital PCR QIAstat-Dx NeuMoDx QuantiFERON Sample technologies(1) Consumables and instruments used in sample collection, stabilization, storage, purification and quality control including QIAsymphony
Slide 29: Sample technologies
Sample technologies Customers Sample collection, stabilization Manual sample preparation and storage solutions Life Sciences Academic Pharma Applied testing Molecular Diagnostics Automated sample preparation Quality control instruments Investor Resource Book 29
Slide 30: The first step in virtually any molecular biology laboratory process
The first step in virtually any molecular Sample technologies biology laboratory process QIAGEN holds leading products in the vast majority of applications mRNA microRNA Total RNA from FFPE tissue Gel extraction Post-reaction cleanup Up to 60% Total RNA from whole (i.e. PCR, enzyme market share in s
Slide 31: Our Sample technologies are the foundation of QIAGEN
Our Sample technologies are the foundation of QIAGEN Sample technologies A portfolio that has grown to address the complete spectrum of processing biological samples Selected biological samples Applications Tissue Stool Input demands Processing Target analytes Cloning qPCR / dPCR Cells Saliva Low /
Slide 32: Building on Sample Technologies solid leadership
Building on Sample Technologies solid leadership Sample technologies Upgrading key automation platforms Comprehensive QIAcube Connect EZ2 Connect QIAsymphony Boost consumables portfolio Launched 2019 Launched 2021 In development Over 300 kits • Any sample format Add photo • Any analyte for QS (DNA,
Slide 33: QIAsymphony – Flagship platform for sample processing
SPOTLIGHT: QIAsymphony – Sample technologies Flagship platform for sample processing Off-the-shelf solutions and customizable protocols to fit wide range of laboratory needs Front-end automation solution for molecular testing Regionalization strategy • US: Focus on sample technologies • Rest-of-worl
Slide 34: Diagnostic solutions
Diagnostic solutions Customers Immune Response Infectious diseases Molecular Diagnostics Women’s Health Oncology and Precision Medicine Investor Resource Book 34
Slide 35: Immune Response: Best-in-class IGRA test for latent tuberculosis
Immune Response: Best-in-class IGRA Diagnostic solutions test for latent tuberculosis What is QuantiFERON? Latent TB testing market QuantiFERON-TB Gold Plus (QFT-Plus) is a simple blood test that aids in the detection >$1 QIAGEN of Mycobacterium tuberculosis, the bacteria which causes tuberculosis (
Slide 36: A growing market demand for modern latent TB testing
A growing market demand for Diagnostic solutions modern latent TB testing What is the difference between latent TB ~70 million latent TB tests per year across the world and active TB? Latent TB infection (LTBI) can persist for weeks, months or North America EMEA Japan years before developing into ac
Slide 37: QuantiFERON offers fully automated workflows for low and high throughput testing
QuantiFERON offers fully automated workflows Diagnostic solutions for low and high throughput testing Enabling hands-free processing of QFT-TB Gold Plus Strong best-in-class High performing Excellent Wide menu: assay: automation: Embedded in market position QFT TB Gold Plus DiaSorin, DiaSorin menu (
Slide 38: QuantiFERON Lyme: Combination of tests allowing a new level of detection
QuantiFERON Lyme: Combination of Diagnostic solutions tests allowing a new level of detection CE-IVD test launched in 2021 FDA approval pending (submitted Dec 2022) Rising occurrence of Lyme disease 40,000 Confirmed cases Potential testing market Europe ~35,000 per year ~12-14 million tests per year
Slide 39: Infectious diseases: New generation of PCR technology for urgent needs
Infectious diseases: New generation Diagnostic solutions of PCR technology for urgent needs Core / Hospital laboratories Near-patient clinical laboratories Hospital and Community hospitals and reference lab networks reference lab “outreach” centers Market opportunity Requirements: Requirements: Mark
Slide 40: QIAstat-Dx: Capturing opportunities in the rapidly growing market
QIAstat-Dx: Capturing Diagnostic solutions opportunities in the rapidly growing market of syndromic testing What is syndromic testing? Syndromic testing is a new approach to molecular diagnostic testing which uses a single test to look for multiple viral, bacterial or fungal infections. Sets of comm
Slide 41: QIAstat-Dx: Reliable, fast and cost-effective diagnosis of complex syndromes
QIAstat-Dx: Reliable, fast and cost-effective Diagnostic solutions diagnosis of complex syndromes Unrivaled ease-of-use Liquid / solid sample input Dry swab sample input Self- contained cartridge Real-time PCR reaction chambers Analytical modules Operational module • Small footprint with More than a
Slide 42: QIAstat-Dx: Expanding menu in U.S. and Europe
QIAstat-Dx: Expanding menu Diagnostic solutions in U.S. and Europe Growing test menu Broadening the addressable market with QIAstat-Dx Rise QIAstat-Dx test menu CE-IVD FDA Gastrointestinal Respiratory SARS CoV-2 Small hospitals Medium-sized hospitals National reference labs, Public health labs Regio
Slide 43: QIAstat-Dx: Novel syndromic testing system delivering unique value
QIAstat-Dx: Diagnostic solutions Novel syndromic testing system delivering unique value QIAstat-Dx (4 scalable slots QIAstat-Dx - Rise Biofire FilmArray Biofire Torch Luminex ePlex Genmark Verigene used for (1 slot) (12 slots) (12 slots) (1 slot) comparison) Throughput (in 8 hours) 28 56 9 108 60 4
Slide 44: NeuMoDx: Bringing simplicity of clinical chemistry to integrated PCR testing
NeuMoDx: Bringing simplicity of clinical Diagnostic solutions chemistry to integrated PCR testing New generation of integrated PCR NeuMoDx differentiation • Easier: Three-step workflow process Two scalable platforms: 96 and 288 • Faster: First results in ~1 hour Fully acquired in September 2020 • Mo
Slide 45: NeuMoDx: Offering a broad CE-IVD menu
NeuMoDx: Offering a broad CE-IVD menu Diagnostic solutions NeuMoDx test menu CE-IVD U.S. HBV 2025 Blood-borne HCV 2025 viruses HIV 2025 CMV 2023 EBV 2.0 2023 BKV Transplant HSV 1/2 Adenovirus HHV6 CT/NG 2023 Sexual / GBS 2024 Reproductive health TV/MG 2025 HPV ~300 GAS cumulative (EUA ) placements(1
Slide 46: NeuMoDx: A unique integrated PCR testing platform
NeuMoDx: A unique integrated PCR testing Diagnostic solutions platform in >$3 billion market opportunity Roche Cobas Hologic Hologic 6800 Roche Cobas Beckman Veris NeuMoDx 288 NeuMoDx 96 Abott Alinity M Panther Panther Fusion (+ Omni LDT 8800 (Discontinued) channel) Volume in '00,000s cm3 38 16 18 2
Slide 47: Oncology and Precision Medicine: QIAGEN as a partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice CDx and LDT Market >25 >$1.1 billion annually ~15% CAGR pharma partnerships Currently mostly LDT’s Day One Lab Readiness program Program designed to further accelerate the access of cancer patients to QIAGEN’s compan
Slide 48: Oncology and Precision Medicine: QIAGEN as a partner of choice
Oncology and Precision Medicine: Diagnostic solutions QIAGEN as a partner of choice QIAGEN molecular diagnostic development 2022 sales: ~$90 million 26 IVD development programs either in pre-clinical or clinical phase • ~50% Pharma co- Offering both development revenues PCR and NGS technologies 20 C
Slide 49: Leveraging a comprehensive Liquid Biopsy portfolio
Leveraging a comprehensive Liquid Biopsy portfolio Diagnostic solutions Addressing opportunities in research and clinical applications to unlock insights from blood Liquid Non-Invasive Cancer Growing Transplant Biopsy Prenatal research and monitoring market trends applications Testing (NIPT) oncolog
Slide 50: Women's Health: Prenatal testing and detection of sexually transmitted diseases
Women’s Health: Prenatal Diagnostic solutions testing and detection of sexually transmitted diseases Cervical cancer screening Digene – Comprehensive range of human papillomavirus DNA test Maternal / Fetal testing AmniSure – For the detection of PAMG-1 in amniotic fluid of pregnant women PartoSure –
Slide 51: PCR / Nucleic Acid amplification
PCR / Nucleic Acid amplification Customers Digital PCR - QIAcuity PCR reagents and instrumentation Life Sciences Academic Pharma Applied testing Customized arrays Investor Resource Book 51
Slide 52: PCR: One of the most widely used tools in molecular biology
PCR: One of the most widely used tools in PCR / Nucleic acid amplification molecular biology What is polymerase chain reaction (PCR)? The process of replicating a specific DNA fragment though a series of thermal cycling to generate thousands to millions of copies. Unlimited customization of arrays t
Slide 53: Digital PCR: A new level of precision and sensitivity
Digital PCR: PCR / Nucleic acid amplification A new level of precision and sensitivity What is digital PCR? Digital PCR is a highly accurate approach for nucleic acid detection and quantification. The basic principle is the same as other PCR technologies Replicating a specific DNA fragment though a
Slide 54: Digital PCR: The latest generation of PCR technology
Digital PCR: The latest generation of PCR technology PCR / Nucleic acid amplification 1st generation 2nd generation 3rd generation Conventional PCR Quantitative RT-PCR (qPCR) Digital PCR (dPCR) Qualitative Relative quantification Absolute quantification Technically simple High accuracy, sensitivity
Slide 55: Leveraging novel technology with QIAcuity digital PCR
Leveraging novel technology with QIAcuity digital PCR PCR / Nucleic acid amplification Enabling access to the Easy-to-use comprehensive PCR market system vs. competition QIAcuity ~$400 million Differentiated nanoplate system QIAcuity One QIAcuity Four QIAcuity Eight Investor Resource Book 55
Slide 56: Five pillars: QIAcuity digital PCR continuing to expand applications
Five pillars: QIAcuity digital PCR continuing to expand applications > 1,000 cumulative placements by end of H1 2022 Highlighted applications Cancer Biopharma Microbial Wastewater Proteomics research detection testing New automated workflow 10 new kits and and custom New QIAGEN dPCR 70% of U.S. stat
Slide 57: PCR enzymes, reagents, and arrays for research workflows
PCR enzymes, reagents, and arrays PCR / Nucleic acid amplification for research workflows QuantiNova: Automatable, ultrafast kits QuantiNova: Automatable, ultrafast kits with in-process controlled safety measures with in-process controlled safety measures • PCR or 1-step & 2-step RT-PCR • Expert-des
Slide 58: Customized arrays: GeneGlobe design and analysis portal
Customized arrays: GeneGlobe design and analysis portal PCR / Nucleic acid amplification for biological content A world of genes, pathways and biological targets Find NGS, PCR and functional analysis assays in the relevant scientific context. Design custom products with full flexibility on target re
Slide 59: Genomics / NGS
Genomics / NGS Customers Universal NGS consumables Illumina collaboration NGS assays Life Sciences Academic Pharma Applied testing Molecular Diagnostics Bioinformatics solutions Investor Resource Book 59
Slide 60: Universal NGS: QIAseq solutions providing high-performance chemistry
Universal NGS: QIAseq solutions providing Genomics / NGS high-performance chemistry Target enrichment and streamlined library preparation leveraging leading sample preparation and bioinformatics QIAGEN NGS differentiation NGS research market Superior technology performance for target enrichment >$80
Slide 61: Partnership to accelerate use of NGS in clinical decision-making
Partnership to accelerate use of NGS Genomics / NGS in clinical decision-making QIAGEN to develop and market NGS IVD kits (including CDx assays) for use on Illumina systems • Integrated with QIAGEN sample technologies, NGS IVD kits and bioinformatics solutions for “Sample to Insight” experience • Ri
Slide 62: QIAGEN Digital Insights: Turning sequencing data into clinically actionable information
QIAGEN Digital Insights: Turning Genomics / NGS sequencing data into clinically actionable information Bioinformatics [baɪ.oʊˌɪnfərˈmætɪks] is an interdisciplinary field that develops methods and software tools for understanding biological data. As an interdisciplinary field of science, bioinformati
Slide 63: The partner of choice for actionable insights from molecular and real-world data
The partner of choice for actionable insights Genomics / NGS from molecular and real-world data Multi-year partnership examples Preferred vendor for Deliver custom NGS Molecular oncology and Genomics England to patient data oncogenetic screening analyze 5 million interpretation for data in Japan’s l
Slide 64: Discovery Insights: Serving the research community
Discovery Insights: Serving the research community Genomics / NGS Example: Analyzing gene expression data from Sample to Insight Biological Freedom sample of Choice Sample Data to Information to Knowledge to data information knowledge to insight NGS library prep Normalization and QC Data Integration
Slide 65: Clinical Insights: Serving the diagnostic laboratories
Clinical Insights: Serving the diagnostic laboratories Genomics / NGS Software platform for scalable, standardized and reproducible variant interpretation VCF FASTQ Variant Variant alignment Variant assessment, Sequencing Final report and quality triage classification and control interpretation ONCO
Slide 66: The insights we gained through QIAGEN's analysis
“The insights we gained through QIAGEN’s analysis point the way to a possible therapeutic target for disease intervention.” DR. MATTHEW DODSON Post-Doctoral Research Associate, Department of Pharmacology and Toxicology, University of Arizona Because of QIAGEN our customers are making improvements in
Slide 67: Sustainability at QIAGEN
rs F re ( Sustainability at QIAGEN
Slide 68: Our vision is aligned with building a sustainable business
Our vision is aligned with building a sustainable business Vision MAKING IMPROVEMENTS IN LIFE Identity POSSIBLE Mission Investor Resource Book 68
Slide 69: Our key levers: Sharpening our focus to optimize our impact
Our key levers: Sharpening our focus to optimize our impact Aligned with U.N. Sustainable Development Goals Environment Social Responsibility for the Serving society environment • Access to healthcare • Minimize carbon footprint • Quality and product safety • Reduce, recycle and • Customer satisfact
Slide 70: Environment
Environment Investor Resource Book 70
Slide 71: Environment: Reducing CO2e emissions across all operations
Environment: Reducing CO2e emissions across all operations Scope 1 and 2 Emissions Scope 3 Emissions 42% reduction by 2030 12.3% reduction by 2030 274k Scope 1 Combustion of fossil fuels Product Purchased Shipping disposal goods 11k Company Vehicles 10k QIAGEN 2021 Emissions Business Waste Scope 2 5
Slide 72: Environment: Integrating sustainability throughout the value chain
Environment: Integrating sustainability throughout the value chain Examples of sustainability in product design • Avoiding materials that cause a lot of damage when they are mined, cannot be recycled or do not decompose • Improving repairability, longevity, and allowing for reuse • Designing product
Slide 73: Environment: New eco-friendly versions of best-selling kits
Environment: New eco-friendly versions of best-selling kits QIAwave RNA Mini Kit / QIAwave DNA Blood & Tissue Kit / QIAwave Plasmid Miniprep Kit Waste tubes made from 100% post-consumer recycled plastic Up to 63% less plastic 86% reduction in concentrated buffers plastic materials Up to 42% No print
Slide 74: Social
Social Investor Resource Book 74
Slide 75: Social: Aiming to provide equitable access to all QIAGEN products
Social: Aiming to provide equitable access to all QIAGEN products Working to ensure developing countries gain access to affordable diagnostics to help prevent and treat diseases Areas of accelerated efforts Committed to expanding screening for tuberculosis (TB) in regions with high rates of disease
Slide 76: Deepening commitment to diversity and inclusion
Deepening commitment to diversity and inclusion Diverse teams strengthen our organization through the variety of ideas, perspectives and approaches Executive Council on Diversity and Strategic initiative to Equal Opportunity Inclusion increase gender (ECEO) Ambassador Program diversity Created to dr
Slide 77: Governance
Governance Investor Resource Book 77
Slide 78: Governance: QIAGEN operates under a two-tier corporate structure
Governance: QIAGEN operates under a two-tier corporate structure Investor Resource Book 78
Slide 79: Governance: International leadership team
Governance: International leadership team with over 200 years of combined industry experience Executive Committee Supervisory Board Chair Chief Executive Officer Lawrence A. Rosen Thierry Bernard Joined 2013 Joined 2015 Chief Financial officer Life Science Metin Colpan Thomas Ebeling Roland Sackers
Slide 80: Governance: Scientific Advisory Board
Governance: Scientific Advisory Board Members Dr. Peter Kaspar Dr. Neville Sanjana Prof. Dr. Ross Levine Leadership positions at Roche Core Faculty Member at the Diagnostics and bioMérieux New York Genome Center and Chair during career in diagnostics, Life Assistant Professor at New Sciences and pha
Slide 81: Your contacts
Your contacts Phoebe Loh Senior Director Calendar Global Investor Relations Q3 2023 results October 2023 Phone: +49 2103 29 11457 Mobile: +49 152 018 11457 Q4 and FY 2023 results February 2024 E-mail: phoebe.loh@qiagen.com Share information Alexandra Koenig Coordinator NYSE: QGEN Investor Relations